Status:
COMPLETED
Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Tanabe Pharma Corporation
Conditions:
Non-erosive Reflux Disease
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to study safety and efficacy of omeprazole standard treatment in a Japanese non-erosive reflux disease population.
Eligibility Criteria
Inclusion
- Patients who identified their predominant symptom as heartburn and were classifiend as Grande M or N according to Hoshihara's modofied version of Los Angeles Classification at esophagogastroduodenoscopy.
Exclusion
- Patients with any ongoing gastrointestinal bleeding at the time of esopgahogastroduodenoscopy, patients with any history of erosive esophagitis or any other major diseases or concommittant drugs likely to interfere with the evaluation of this study
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
July 1 2004
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT00259077
Start Date
October 1 2003
End Date
July 1 2004
Last Update
January 24 2011
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Asa, Japan
2
Beppu, Japan
3
Chiyoda City, Japan
4
Fujieda, Japan